EPOP (Gene)

Organism:

Homo sapiens

Synonyms:C17orf96, ENTREZ:100170841, EPOP, HGNC:34493, MIM:617795, NM_001130677, NP_001124149, PRR28, elongin BC and polycomb repressive complex 2 associated protein

Id:ENSG00000273604

Entrez:100170841

Ensembl:ENSG00000273604

Description:elongin BC and polycomb repressive complex 2 associated protein

Predicted to enable chromatin binding activity. Predicted to be involved in several processes, including histone H2B conserved C-terminal lysine deubiquitination; neuron fate commitment; and stem cell differentiation. Predicted to be located in chromosome. Predicted to colocalize with ESC/E(Z) complex and elongin complex. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View EPOP's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with EPOP.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using EPOP.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for EPOP.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with EPOP.

Results found

Linked to

	Label	Description
	GSE114883 romidepsin T cell 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE187006 3 V 2 VALPROIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 0 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE114883 romidepsin T cell 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE93156 idelalisib B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE114883 romidepsin T cell 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE218773 ABL2 knockdown Hep-G2 2 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 6 v 8 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE187006 3 V 2 VALPROIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE188728 GSE188730 BRG1 HSA BCL7 knockdown B cell 3 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE114883 romidepsin T cell 0 v 4 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE114883 romidepsin T cell 0 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 cisplatin 7 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE93156 idelalisib B cell 1 v 0 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.